Scarica l'app Stockscreener
3.18
4.50%
-0.15
Dopo l'orario di chiusura:
3.19
0.010
+0.31%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.33
Aprire:
$3.35
Volume 24 ore:
592.50K
Relative Volume:
0.42
Capitalizzazione di mercato:
$155.29M
Reddito:
$103.00K
Utile/perdita netta:
$-42.47M
Rapporto P/E:
-1.6737
EPS:
-1.9
Flusso di cassa netto:
$-34.30M
1 W Prestazione:
+0.63%
1M Prestazione:
-14.40%
6M Prestazione:
+19.10%
1 anno Prestazione:
+70.97%
Intervallo 1D:
$3.15
$3.37
Intervallo di 1 settimana:
$3.11
$3.42
Portata 52W:
$1.38
$4.50
Checkpoint Therapeutics Inc Stock (CKPT) Company Profile
Nome
Checkpoint Therapeutics Inc
Settore
Industria
Telefono
781-652-4500
Indirizzo
95 SAWYER ROAD, WALTHAM, NY
Confronta CKPT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CKPT
Checkpoint Therapeutics Inc
|
3.18 | 155.29M | 103.00K | -42.47M | -34.30M | -1.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Checkpoint Therapeutics Inc Stock (CKPT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-13 | Iniziato | D. Boral Capital | Buy |
| 2022-07-14 | Ripresa | B. Riley Securities | Buy |
| 2021-06-09 | Iniziato | B. Riley Securities | Buy |
| 2021-01-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-05-29 | Iniziato | Lake Street | Buy |
| 2017-12-08 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Checkpoint Therapeutics Inc Borsa (CKPT) Ultime notizie
Short Interest in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Increases By 17.5% - MarketBeat
Reviewing LifeVantage (NASDAQ:LFVN) & Checkpoint Therapeutics (NASDAQ:CKPT) - Defense World
Checkpoint Therapeutics (NASDAQ:CKPT) Coverage Initiated by Analysts at D. Boral Capital - Defense World
Checkpoint Therapeutics stock initiated at Buy Rating by Borak Capital - Investing.com Canada
This PG&E Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
D. Boral Capital Initiates Coverage on Checkpoint Therapeutics (NASDAQ:CKPT) - MarketBeat
D. Boral Capital Initiates Coverage of Checkpoint Therapeutics (CKPT) with Buy Recommendation - MSN
Checkpoint Therapeutics CFO signs new executive agreement By Investing.com - Investing.com Australia
Checkpoint Therapeutics CFO signs new executive agreement - Investing.com India
Geode Capital Management LLC Buys 124,787 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) - Defense World
Checkpoint Therapeutics Signs Executive Agreement with CFO - TipRanks
Checkpoint Therapeutics Inc (NASDAQ: CKPT) Today’s Hot Stock - Stocks Register
State Street Corp Grows Stock Holdings in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) - Defense World
Head to Head Contrast: Tyra Biosciences (NASDAQ:TYRA) and Checkpoint Therapeutics (NASDAQ:CKPT) - Defense World
Checkpoint Therapeutics CFO sells $1.08 million in stock - Investing.com India
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO Sells 268,432 Shares - MarketBeat
James F. Oliviero III Sells 220,230 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Stock - MarketBeat
Checkpoint Therapeutics CFO sells $1.08 million in stock By Investing.com - Investing.com Canada
Checkpoint Therapeutics CEO sells $3.07 million in stock By Investing.com - Investing.com Canada
Checkpoint Therapeutics: Updating My Strategy After Unloxcyt's Approval (NASDAQ:CKPT) - Seeking Alpha
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT for Treatment of Advanced Cutaneous Squamous Cell Carcinoma - Defense World
Affimed Shares Fall 32% on Clinical Update - Yahoo Finance
Fortress Biotech subsidiary gains FDA approval for cSCC therapy - Investing.com
Soligenix initiates confirmatory Phase 3 trial of HyBryte - Yahoo Finance
Checkpoint Therapeutics (NASDAQ:CKPT) Receives Buy Rating from HC Wainwright - Defense World
Checkpoint Therapeutics (NASDAQ:CKPT) Price Target Raised to $7.00 at Lake Street Capital - Defense World
FDA Tracker: Neurocrine, Checkpoint Score FDA Approvals - BioSpace
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Short Interest Up 9.0% in November - MarketBeat
Investors Purchase Large Volume of Call Options on Checkpoint Therapeutics (NASDAQ:CKPT) - MarketBeat
FDA Approves Cosibelimab for Cutaneous SCC - Medscape
Checkpoint Therapeutics (NASDAQ:CKPT) Price Target Raised to $7.00 - MarketBeat
FDA Approves Checkpoint Therapeutics' Skin Cancer Drug One Year After Rejection - Yahoo Finance
HC Wainwright Reaffirms Buy Rating for Checkpoint Therapeutics (NASDAQ:CKPT) - MarketBeat
US Stocks To Open Higher Ahead Of Fed's Decision This Week: Analyst Says 'Santa Comes Later In December' - Benzinga
FDA approves Checkpoint Thera’s Unloxcyt - The Pharma Letter
Pre-market Movers: EWTX, TNXP, LNSR, VRDN... - RTTNews
Checkpoint stock on watch after FDA nod (CKPT:NASDAQ) - Seeking Alpha
Checkpoint Therapeutics' Shares Rise After Securing First FDA Approval - Marketscreener.com
Checkpoint Therapeutics Gets Its First FDA Approval - Marketscreener.com
US FDA approves Checkpoint's skin cancer drug - Reuters.com
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl) - GlobeNewswire
Checkpoint Therapeutics Secures First FDA Approval for Novel Cancer Drug UNLOXCYT in $1B+ Market - StockTitan
Absci highlights progress, updates across proprietary pipeline - Yahoo Finance
Lucid Group Inc (LCID-Q) QuotePress Release - The Globe and Mail
Nine PDUFA dates on FDA’s December calendar - BioCentury
Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend - cnhinews.com
Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail
Checkpoint Therapeutics stock hits 52-week high at $3.98 By Investing.com - Investing.com South Africa
Checkpoint Therapeutics stock hits 52-week high at $3.98 - Investing.com
Checkpoint Therapeutics Inc Azioni (CKPT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.65%
4.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):